JAK2 Expression in Androgenetic Alopecia Before and After Topical Minoxidil
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexMale
Age18-50
SponsorKasr El Aini Hospital
About this trial
Androgenetic alopecia is a common form of progressive hair loss. This prospective single-arm pre-post interventional study aims to assess tissue Janus Kinase 2 (JAK2) expression in patients with androgenetic alopecia by comparing balding and non-balding scalp at baseline, and to evaluate changes in JAK2 expression in balding scalp after 3 months of topical minoxidil 5% therapy. Clinical response will be assessed using standardized trichoscopic parameters.
Eligibility criteria
Qualifiers
Male adults aged 18 to 50 years with androgenetic alopecia.
Mild to moderate disease severity, defined as Hamilton-Norwood scale II to V.
Patients who are treatment-naive or willing to undergo an adequate washout period for prior hair loss therapies of at least 1 month.
Willing and able to provide written informed consent.
Disqualifiers
Other types of hair loss, including inflammatory or scarring alopecia.
Inflammatory scalp dermatoses, such as psoriasis or seborrheic dermatitis.
Use of systemic immunosuppressants, JAK inhibitors, or systemic corticosteroids within the last 12 months.
History of severe systemic disease, including renal, cardiovascular, or hepatic disease.
Trial design
Treatments tested in this trial
- Topical Minoxidil 5% Solution
- Scalp Punch Biopsy
- Tissue JAK2 Protein Measurement by ELISA
Treatment groups
25 Participants
are divided into 1 treatment groupSponsors and collaborators
Source ClinicalTrials.gov